明德生物：2025年全年净利润同比预减75.85%—83.90%

Core Viewpoint - Mingde Bio has announced an annual performance forecast indicating a significant decline in net profit for 2025, with expectations of a net profit attributable to shareholders ranging from 12 million to 18 million yuan, representing a year-on-year decrease of 75.85% to 83.90% [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -98 million and -78 million yuan for 2025 [1] - The decline in net profit is primarily attributed to a substantial decrease in investment income and other income, along with an increase in credit impairment losses [1] Government Subsidies and Investment Income - During the reporting period, the amount of government subsidies received by the company decreased by over 40 million yuan compared to the same period last year [1] - Investment income has also seen a decline of over 30 million yuan year-on-year, influenced by the continuous decline in domestic financial market interest rates and lower yields on the company's financial products [1] Credit Impairment Losses - The company experienced a reduction in the collection of overdue accounts receivable compared to the previous year, leading to a decrease of over 30 million yuan in the reversal of impairment provisions for receivables that underwent individual impairment testing [1]